Education
About Us
Working with TipRanks
Follow Us
TELA Bio (TELA)
NASDAQ:TELA
TELA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.86 - $6.50
Previous CloseN/A
Volume34.27K
Average Volume (3M)386.50K
Market Cap
$37.96M
Enterprise Value$111.41M
Total Cash (Recent Filing)-$11.35M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.49
Next Earnings
May 08, 2025EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.39
Shares Outstanding39,554,770
10 Day Avg. Volume96,658
30 Day Avg. Volume386,499
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.84
Price to Cash Flow (P/CF)-1.60
P/FCF Ratio0.00
Enterprise Value/Market Cap2.94
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit2.40
Enterprise Value/Ebitda-3.52
Forecast
1Y Price Target
$5.50Price Target Upside472.92% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
TELA Bio News
PremiumCompany Announcements
TELA Bio’s Earnings Call: Challenges and Optimism for 2025
---
Bulls Say, Bears Say
Bulls Say
Market PositionTELA's products are considered best-in-class, supported by strong clinical data and trends in robotic adoption.
Market PotentialThe product portfolio and growth rate support the potential for multiple expansion, making the current valuation appear too low.
Product InnovationNew products like inguinal hernia and Liquifix have been successful since their launch, providing TELA opportunities in high-volume procedures.
Bears Say
Financial PerformanceTELA reported Q4 results, which were well below estimates, with a significant sales force turnover impacting the company's performance.
Financial StabilityThe company may need another round of financing to fund operations, which could negatively impact the stock.
Sales Force ChallengesThe departure of 11 of 69 high-performing territory managers led to a significant drop in sales.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
TELA FAQ
What was TELA Bio’s price range in the past 12 months?
TELA Bio lowest stock price was $0.86 and its highest was $6.50 in the past 12 months.
What is TELA Bio’s market cap?
TELA Bio’s market cap is $37.96M.
When is TELA Bio’s upcoming earnings report date?
TELA Bio’s upcoming earnings report date is May 08, 2025 which is in 11 days.
How were TELA Bio’s earnings last quarter?
TELA Bio released its earnings results on Mar 20, 2025. The company reported -$0.23 earnings per share for the quarter, missing the consensus estimate of -$0.212 by -$0.018.
Is TELA Bio overvalued?
According to Wall Street analysts TELA Bio’s price is currently Undervalued.
Does TELA Bio pay dividends?
TELA Bio does not currently pay dividends.
What is TELA Bio’s EPS estimate?
TELA Bio’s EPS estimate is -0.2.
How many shares outstanding does TELA Bio have?
TELA Bio has 39,554,770 shares outstanding.
What happened to TELA Bio’s price movement after its last earnings report?
TELA Bio reported an EPS of -$0.23 in its last earnings report, missing expectations of -$0.212. Following the earnings report the stock price went down -37.179%.
Which hedge fund is a major shareholder of TELA Bio?
Currently, no hedge funds are holding shares in TELA
---
TELA Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.50 (472.92% Upside)
$5.50 (472.92% Upside)
Blogger Sentiment
Bullish
TELA Sentiment 70%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $265.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 3.6%
Last 30 Days ▲ 11.6%
Last 30 Days ▲ 11.6%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-78.15%
12-Months-Change
Fundamentals
Return on Equity
-159.87%
Trailing 12-Months
Asset Growth
11.89%
Trailing 12-Months
Company Description
TELA Bio
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. The company markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
---
TELA Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
While TELA Bio experienced significant challenges in Q4 2024 due to sales force disruptions and external factors, the company maintains a positive outlook for 2025 with strong product portfolio expansion and growth expectations. The highlights of full-year revenue growth and new product launches are tempered by the Q4 setbacks and sales force challenges.Read More>---
TELA Stock 12 Month Forecast
Average Price Target
$5.50
▲(472.92% Upside)
Technical Analysis
Best Analysts Covering TELA
1 Year
1 Year Success Rate
5/21 ratings generated profit
1 Year Average Return
-26.60%
reiterated a buy rating last month
Copying David Turkaly's trades and holding each position for 1 Year would result in 23.81% of your transactions generating a profit, with an average return of -26.60% per trade.
---